Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Pfizer Terms Canadian News Report Questioning Celebrex Safety

By Pharmaceutical Processing | November 8, 2004

NEW YORK, NY (November 8, 2004) – Pfizer Inc. last week labeled “misleading” a report in Canada’s National Post newspaper concerning the cardiovascular safety of Celebrex.

Pfizer said the news report was based on voluntary spontaneous event reporting to Canadian Health authorities and was “not supported by any clinical or epidemiological studies.” The company said the report “has the potential to cause undue confusion among patients and physicians.”

“The safety profile for Celebrex is well-established and is supported by extensive clinical studies in Canada and around the world,” Pfizer said in a statement issued Thursday.

Voluntary spontaneous event reporting to health authorities is not designed and cannot be used to determine cause and effect, the company said. “It is essential to remember that the information provided is uncontrolled and may be second-hand or incomplete,” the Pfizer statement continued.

According to Pfizer, Health Canada has acknowledged these limitations, noting “there hasn’t been a causal link established,” and that “these datacontain no information about patients’ underlying medical conditions.”

Pfizer said that millions of patients have been prescribed Celebrex since its first approval in 1998 and large-scale clinical studies of up to four years showed no increased cardiovascular safety risk.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE